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Abstract
Dual-specificity phosphatase 2 (Dusp2; also called phosphatase of activated cells 1, PAC1) is 
highly expressed in activated immune cells. We examined whether a potential inhibitor of Dusp2, 
salubrinal, prevents inflammatory cytokine expression in immune cells and arthritic responses in a 
mouse model of anti-collagen antibody-induced arthritis (CAIA). Salubrinal is a synthetic 
chemical that inhibits de-phosphorylation of eukaryotic translation initiation factor 2 alpha 
(eIF2α). In this study, we examined the effects of salubrinal on expression of inflammation linked 
genes as well as a family of DUSP genes using genome-wide microarrays, qPCR, and RNA 
interference. We also evaluated the effects of salubrinal on arthritic responses in CAIA mice using 
clinical and histological scores. The results revealed that salubrinal decreased inflammatory gene 
expression in macrophages, T lymphocytes, and mast cells. Dusp2 was suppressed by salubrinal in 
LPS-activated macrophages as well as PMA/ionomycin-activated T lymphocytes and mast cells. 
Furthermore, a partial silencing of Dusp2 downregulated IL1β and Cox2, and the inflammatory 
signs of CAIA mice were significantly suppressed by salubrinal. Collectively, this study presents a 
novel therapeutic possibility of salubrinal for inflammatory arthritis such as RA through inhibition 
of Dusp2.
© 2015 Published by Elsevier Inc.
This manuscript version is made available under the CC BY-NC-ND 4.0 license.
*Corresponding Author: Kazunori Hamamura, PhD/DDS (hamak@dpc.agu.ac.jp), Department of Pharmacology, School of Dentistry, 
Aichi-Gakuin University, 1-100 Kusumoto-cho, Chikusa-ku, Nagoya 464-8650, Japan, Phone: +81-52-757-6743, Fax: 
+81-52-752-5988. 
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Author contributions
Conception and experimental design: Hamamura K, Sudo A, Yokota H. data collection and interpretation: Hamamura K, 
Nishimura A, Chen A, Takigawa S. drafted manuscript: Hamamura K, Chen A, Yokota H.
Competing interests
None
NIH Public Access
Author Manuscript
Cell Signal. Author manuscript; available in PMC 2016 April 01.
Published in final edited form as:
Cell Signal. 2015 April ; 27(4): 828–835. doi:10.1016/j.cellsig.2015.01.010.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Keywords
Salubrinal; CAIA; microarray; Inflammation; Dusp2 (PAC1)
1. Introduction
Dual-specificity phosphatases (DUSPs) are a family of phosphatases that de-phosphorylate 
both phosphotyrosine and phosphoserine/phosphothreonine residues [1]. Among 30 putative 
DUSP genes, many of them regulate mitogen-activated protein kinases (MAPKs) and thus 
referred to as MAPK phosphatases [2]. Dusp2 (PAC1) is one of those MAPK phosphatases, 
and it is predominantly expressed in immune cells [2, 3]. Dusp2 is highly expressed in 
immune cells, in particular, of patients with inflammatory arthritis, such as in rheumatoid 
arthritis (RA), and Dusp2 knockout mice present a significant reduction in inflammatory 
responses [4].
Because of its elevated expression in RA, we investigated herein a possibility of regulating 
RA symptoms through the inhibition of Dusp2. RA is the most common type of autoimmune 
arthritis, in which the immune system mistakenly attacks joint tissues [5]. There is no cure 
for RA, but synthetic agents such as methotrexate and hydroxychloroquine are commonly 
prescribed as disease-modifying antirheumatic drugs [6], as well as biologic response 
modifiers such as Etanercept and Adalimumab [7, 8]. To our knowledge, however, little is 
known about agents that modulate expression of Dusp2.
In the current study, we focused on a synthetic chemical agent, salubrinal, as a candidate 
drug for the modulation of Dusp2. Salubrinal is a 480-Da agent that inhibits a serine 
phosphatase, protein phosphatase 1 (PP1), and elevates the phosphorylation of eukaryotic 
translation initiation factor 2 alpha (eIF2α) [9]. Through eIF2α-mediated transcriptional and 
translational regulation, salubrinal has been shown to exhibit multiple beneficial effects on 
skeletal tissue. First, salubrinal downregulates expression and activity of MMP13 in 
chondrocytes by inactivating p38 and NFκB signaling pathways [10]. Second, the elevated 
phosphorylation of eIF2α by salubrinal activates translation of activating transcription factor 
4 (ATF4), which stimulates osteoblastogenesis and bone formation [11]. Third, salubrinal 
suppresses receptor activator of nuclear factor kappa-B ligand (RANKL)-induced 
osteoclastogenesis followed by bone resorption by inactivating nuclear factor of activated T-
cells, cytoplasmic 1 (NFATc1) in bone marrow-derived cells [12, 13]. We performed herein 
genome-wide expression analysis in order to evaluate un-examined roles of salubrinal in the 
transcriptional regulation of varying phosphatases including Dusp2 and other Dusp family 
genes.
In this study, we conducted in vitro analysis using 4 sources of immune cells (RAW264.7 
macrophages, primary macrophages, Jurkat T lymphocytes, and HMC-1.1 mast cells). 
Salubrinal’s effects on inflammatory responses were examined through genome-wide 
microarray experiments followed by a principal component analysis (PCA). PCA 
highlighted a set of genes which are most significantly affected by administration of 
salubrinal, including DUSP family genes. To examine physiological effects of salubrinal in 
inflammatory arthritis, we conducted in vivo analysis using a mouse model of anti-collagen 
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antibody-induced arthritis (CAIA) [14]. The CAIA model offers several key advantages 
over the classic collagen-induced arthritis (CIA) model, including rapid disease onset and 
synchronicity [15]. To evaluate salubrinal’s role in the suppression of inflammatory 
responses in CAIA mice, we quantified inflammatory symptoms using a clinical scoring 
system and a histological scoring system.
2. Materials and methods
2.1 Cell Culture
Mouse bone marrow cells and RAW264.7 macrophages were cultured in αMEM with 10% 
FBS and antibiotics. Bone marrow cells were cultured with 10 ng/ml M-CSF (macrophage 
colony-stimulating factor; PeproTech, Rocky Hills, NC, USA) for 3 days, and the surface-
attached cells were used as primary macrophages. Jurkat T lymphocytes and HMC-1.1 mast 
cells were cultured in RPMI 1640 and IMDM with 1-thioglycerol, respectively. RAW264.7 
cells were activated by 0.1 or 1 µg/ml lipopolysaccharide (LPS), while Jurkat cells by 100 
nM phorbol myristate acetate (PMA) and 1 µM ionomycin.
2.2 Induction of Anti-collagen Antibody Induced Arthritis (CAIA) and Clinical Score
Using Balb/c female mice (~nine weeks old), CAIA was induced by intravenous injection of 
a 2 mg cocktail of ArthritoMAb™ antibodies (MD Bioproducts, St Paul, MN, USA) on day 
0 followed by intraperitoneal injection of 100 µg LPS on day 3 [14, 15]. Mice were 
randomly divided into a placebo group and a salubrinal-treated group. Salubrinal (2.0 
mg/kg) was intravenously administered daily from day 0, while a solvent (49.5% PEG 400 
and 0.5% Tween 80 in PBS) was administered to the placebo group.
The progression of CAIA was evaluated using a clinical score [16]: “0.25” = swelling in a 
single digit; “0.5” = swelling in more than one digit; “1” = swelling and erythema of the 
paw; “2” = swelling of the paw and ankle; and “3” = complete inflammation of the paw. The 
maximum possible score for each mouse was 12. We also measured thickness of fore and 
hind paws.
2.3 Histological Evaluation
Hind paws were harvested and decalcified in 10% EDTA for 2 weeks. They were embedded 
in paraffin, sectioned at 4 µm thickness, and stained with hematoxylin and eosin (H&E). The 
progression of CAIA was histologically evaluated using the scoring system [17]: “0” = 
normal; “1” = weak leukocyte infiltration but no erosion; “2” = modest infiltration and weak 
erosion; “3” = severe infiltration and invasion of bones; and “4” = loss of bone integrity.
2.4 Microarray
Genome-wide expression analysis was conducted using RAW264.7 cells (Mouse Gene 2.0 
ST arrays, Affymetrix) as well as Jurkat cells (Human Gene 2.0 ST arrays, Affymetrix). 
Three groups for RAW264.7 cells were CN (control), LPS, and Sal (LPS + Sal), while for 
Jurkat cells they were CN (control), PMA (PMA/ionomycin), and Sal (PMA/ionomycin + 
Sal). The concentration of LPS, PMA, ionomycin, and salubrinal were 0.1 µg/ml, 100 nM, 1 
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µM, and 10 µM, respectively, and these agents were administered 0 h. Each group consisted 
of triplicate samples, which were harvested 6 h.
We selected a group of “activated” genes, whose mRNA levels were lowered by LPS or 
PMA/ionomycin (p < 0.05) and the decrease was reversed by salubrinal (p < 0.05). We also 
identified a group of “suppressed” genes, whose mRNA levels were elevated by the 
inducing agents (p < 0.05) and the elevation was suppressed by salubrinal (p < 0.05). 
Principal component analysis (PCA) was performed on those activated and suppressed genes 
[18]. The nine samples in total were positioned in the plane of the first and second principal 
axes.
Using WebGestalt, salubrinal-driven signaling pathways were identified [19]. Based on the 
hypergeometric statistical test with a Bonferroni correction (p<0.05), we selected pathways 
that significantly enriched the appearance of the activated or suppressed genes. We also 
plotted the location of each gene on the first and second principal component axes and 
highlighted the genes involved in three representative pathways.
2.5 Quantitative Real-time PCR
Total RNA was extracted and reverse transcription was conducted with high-capacity cDNA 
reverse transcription kits (Applied Biosystems, Carlsbad, CA, USA). Quantitative real-time 
PCR was performed using Power SYBR green PCR master mix kits (Applied Biosystems). 
We evaluated mRNA levels of Cox2, Dusp2, IL1β, IL2, IL13, and TNF using the PCR 
primers (Table 1). GAPDH was used for internal control [20].
2.6 Knockdown of Dusp2 by siRNA
RAW264.7 cells were treated with siRNA specific to Dusp2 or nonspecific control siRNA 
(Life Technologies) (Table 1). Cells were transiently transfected in Opti-MEM I medium 
using Lipofectamine RNAiMAX (Life Technologies). The efficiency of silencing was 
assessed with PCR 48 h after transfection.
2.7 Statistical Analysis
For in vitro experiments, 3 to 4 independent experiments were conducted. Data were 
expressed as mean ± S.D. Statistical significance was evaluated using Student’s t-test at 
p<0.05. Single and double asterisks indicate p<0.05 and p<0.01, respectively.
3. Results
3.1 Suppression of Inflammatory Cytokines and Cox2 by Salubrinal
Incubation of RAW264.7 macrophages with 10 µM salubrinal for 6 h and 24 h significantly 
suppressed IL1β and Cox2 mRNAs (Figure 1A and B). The suppression of these mRNAs 
was also observed in primary macrophages by 5 or 10 µM salubrinal (Fig. 1C). Furthermore, 
the elevation of IL2 mRNA in Jurkat cells as well as the increase in TNF and IL13 mRNAs 
in HMC-1.1 cells by PMA/ionomycin was attenuated by 5 or 10 µM salubrinal (Fig. 1D & 
E).
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3.2 Genome-wide Modulation of Inflammatory Responses by Salubrinal
PCA revealed that along the first primary component axis, LPS or PMA/ionomycin driven 
alterations was partially restored by salubrinal (Fig. 2A & B). A pathway analysis showed 
the enrichment of several inflammation-related pathways in both the RAW246.7 and Jurkat 
cells (Fig. 2C & D & Fig. S1). Three pathways (B cell receptor signaling, Toll-like receptor 
signaling, and Natural killer cell mediated cytotoxicity) were commonly enriched between 
the two cell types. The genes involved in each pathway were identified on the first and 
second principal component axes.
When we focused on the genes commonly altered in both types of cells and selected either 
“activated” or “suppressed” by salubrinal, a consensus expression pattern emerged, and 
Dusp2 was found to be suppressed in both cell lines (Fig. 3A). The activated and suppressed 
genes were identified on the first and second principal component axes in RAW246.7 cells 
(Fig. 3B) and Jurkat cells (Fig. 3C). Of note, Dusp2 was located near the lower end of the 
suppressed gene cluster in both cell types.
3.3 Salubrinal-driven Suppression of Dusp2
Among the Dusp genes, the genes suppressed in RAW264.7 cells included Dusp2, Dusp5, 
and Dusp16, while in Jurkat cells they were Dusp2, Dusp4, Dusp6, Dusp8, Dusp18, and 
Dusp22 (Fig. 4A & B). Dusp2 was the only gene whose upregulation by LPS or PMA/
ionomycin was suppressed by salubrinal in two cell lines. No Dusp genes were activated in 
both RAW264.7 and Jurkat cells. In RAW264.7, primary macrophages, Jurkat T 
lymphocytes, and HMC-1.1 mast cells, qPCR confirmed that the mRNA level of Dusp2 was 
elevated by LPS or PMA/ionomycin and its upregulation was decreased by 5 or 10 µM 
salubrinal (Fig. 4C – G).
3.4 Downregulation of IL1β and Cox2 by Partial Silencing of Dusp2
RNA interference using siRNA specific to Dusp2 revealed that partial silencing of Dusp2 
significantly suppressed LPS-driven upregulation of IL1β and Cox2 in RAW264.7 cells 
(Fig. 4H & I). In the presence of LPS, treatment with Dusp2 siRNA reduced the level of 
IL1β mRNA by 43%, and Cox2 by 17%.
3.5 Salubrinal-driven Suppression of the Progression of CAIA
Salubrinal significantly suppressed inflammation of the paws of CAIA mice (Fig. 5A & B). 
For instance, the clinical scores were 1.94±1.7 (placebo) and 0.31±0.6 (salubrinal) on day 6; 
and 4.63±3.4 (placebo) and 1.09±1.6 (salubrinal) on day 12 (Fig. 5C). Consistent with the 
clinical scores, the thickening of the paws was also reduced in the salubrinal-treated group 
(Fig. 5D & E). Furthermore, salubrinal reduced the histological scores from 1.47±1.10 
(N=16; placebo) to 0.59±0.64 (N =16; salubrinal) (p=0.01) (Fig. 5E & F).
4. Discussion
We showed that salubrinal downregulated the expression of Dusp2 and inflammatory genes 
in immune cells in vitro, and its administration to CAIA mice significantly reduced 
inflammatory responses in vivo. In the in vitro assays, genome-wide microarray analysis 
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revealed that Dusp2 may potentially mediate salubrinal’s partial attenuation of the 
inflammatory effects of LPS and PMA/ionomycin in RAW264.7 and Jurkat cell cultures. In 
the in vivo analysis with CAIA mice, inflammation was induced by the administration of a 
cocktail of antibodies that recognize auto-antigenic epitopes in type II collagen, which offers 
a rapid disease onset and synchronicity over the classic collagen-induced arthritis (CIA) 
model. The clinical and histological scores as well as thickness measurements of the paws in 
CAIA mice support the efficacy of salubrinal in suppression of inflammation. On day 12, for 
instance, the administration of salubrinal improved the clinical scores from 4.63±3.4 to 
1.09±1.6, and the histological scores from 1.47±1.10 to 0.59±0.64.
Genome-wide expression analysis using PCA and the classification of suppressed and 
activated genes revealed that salubrinal significantly suppressed Dusp2 expression. In DUSP 
genes highlighted in Figure 4, 4 DUSP genes (DUSP1, DUSP2, DUSP4, and DUSP5) are 
considered to be MAPK phosphatases that dephosphorylate Erk, Jnk, and p38 MAPK [2, 3]. 
Among those 4 DUSP genes, Dusp2 is known to be an activator of inflammatory responses 
in T and B cells [4]. Expression analysis revealed that Dusp2 was the only DUSP gene that 
was downregulated by salubrinal in both RAW264.7 and Jurkat cells. For instance, Dusp5 
was reduced by salubrinal in RAW264.7 cells and Dusp4 in Jurkat cells, but not vice versa. 
Salubrinal activated Dusp6 in RAW264.7 cells but inhibited it in Jurkat cells.
We have previously shown using C28/I2 chondrocytes that salubrinal downregulates 
cytokine-induced inflammatory responses through the inactivation of NFκB and p38 MAPK 
[10]. Using RAW264.7 cells, it is also reported that salubrinal suppresses expression of pro-
inflammatory cytokines by inactivating NFκB signaling [21]. In cystic fibrosis airway cells 
that induce an inflammatory lung disease, salubrinal is reported to reduce inflammatory 
responses through eIF2α-mediated downregulation of p38 MAPK [22]. We also observed in 
C28/I2 chondrocytes that salubrinal reduces activity of Src tyrosine kinases through the 
elevation of eIF2α phosphorylation [23]. Of note, Src kinases play important roles in 
production and activation of various cytokines [24]. Collectively, a salubrinal-Dusp2 
regulatory axis that links Dusp2, p38 MAPK, NFκB, and Src kinases through eIF2α 
signaling is yet to be identified.
Genes involved in inflammatory responses differ depending on the types of immune cells. 
Among three cell lines (RAW264.7, Jurkat T lymphocytes, and HMC-1.1 mast cells) 
together with primary macrophages, salubrinal suppressed the elevation of IL1β and Cox2 in 
each cell type. Salubrinal reduced PMA/ionomycin-driven IL2 expression in Jurkat 
lymphocytes and decreased the level of TNF and IL13 mRNAs in HMC-1.1 mast cells. Of 
note, these cytokines (IL1β, IL2, IL13, and TNF) are selectively activated in different types 
of immune cells [25, 26]. Biologic drugs against TNFα, CD20, and IL1/IL6 receptors have 
been developed for treatment of RA [27, 28]. They can lessen RA symptoms and delay 
radiographic progression, but they may also present increased risk of infections.
Besides the suppression of inflammatory responses, the protection of bone erosions at the 
joint margins and in subchondral bone is critically important for patients with RA [29]. 
Salubrinal’s advantage is that it attenuates bone destruction by eIF2α-mediated 
downregulation of NFATc1, a master transcription factor for osteoclastogenesis [11]. 
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Furthermore, salubrinal can downregulate MMP13, a collagenase that digests not only 
aggrecan in cartilage but also collagen in bone [10].
In order to further evaluate salubrinal as a drug candidate for treatment of inflammatory 
arthritis such as RA, there are several further studies to be done. First, it is necessary to 
understand salubrinal’s effect not only on immune cells but also on synovial fibroblasts, 
since synovial fibroblasts in the rheumatoid synovium are aggressive drivers of cartilage 
destruction [30]. Second, although the CAIA mouse model can induce inflammatory 
responses in a short period of time, it is necessary to monitor the efficacy of salubrinal over 
an extended period of time and determine appropriate dosage and treatment duration. Third, 
it is important to discover whether salubrinal can be administered with other agents, such as 
disease-modifying antirheumatic drugs or biological response modifiers, to induce 
synergistic therapeutic effects [31].
In summary, this study demonstrates that administration of salubrinal reduces expression of 
Dusp2 as well as inflammatory cytokines such as IL1β, IL2, IL13, and TNF in immune 
cells. Furthermore, salubrinal suppresses inflammatory responses in CAIA mice. Although it 
is premature to conclude with the current pre-clinical study, further studies on toxicology 
and dose dependence could warrant the development of preventive and therapeutic uses of 
salubrinal for inflammatory arthritis such as RA.
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Highlights
• Salubrinal prevents inflammatory responses in a mouse model of arthritis.
• Genome-wide analysis reveals Dusp2 as a primary target of salubrinal.
• IL1β was downregulated by salubrinal and a partial silencing of Dusp2.
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Figure 1. 
Suppression of inflammatory genes by salubrinal (Sal). (A&B) Effects of 10 µM salubrinal 
on IL1β and Cox2 mRNAs in RAW264.7 cells at 6 h and 24 h, respectively. (C) Effects of 5 
or 10 µM salubrinal on IL1β and Cox2 mRNAs in primary macrophages at 6 h. (D) Effects 
of 5 or 10 µM salubrinal on IL2 mRNA in Jurkat cells at 6 h. (E) Effects of 10 µM salubrinal 
on TNF and IL13 mRNAs in HMC-1.1 cells at 4 h.
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Figure 2. 
PCA and pathway prediction. (A) PCA for RAW264.7 cells. (B) PCA for Jurkat cells. 
(C&D) Enriched KEGG pathways by genes activated and suppressed by salubrinal in 
RAW264.7 and Jurkat cells, respectively. Three pathways, common to RAW264.7 and 
Jurkat cells, are highlighted. Genes in each pathway are identified on the first and second 
principal component axes.
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Figure 3. 
(A) Heatmaps showing the top 10 genes highly activated or suppressed by 10 µM salubrinal 
commonly in RAW264.7 and Jurkat cells. Note that CN=control, and Sal=salubrinal in the 
presence of LPS (RAW264.7) or PMA/ionomycin (Jurkat). (B) Genes activated (red) or 
suppressed (blue) in RAW264.7 cells on the first and second principal component axes. (C) 
Genes activated (red) or suppressed (blue) in Jurkat cells on the first and second principal 
component axes.
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Figure 4. 
Salubrinal-driven suppression of Dusp2 upregulation. Note that CN=control, and 
Sal=salubrinal in the presence of LPS (RAW264.7) or PMA/ionomycin (Jurkat). (A) 
Heatmap of DUSP genes in RAW264.7 cells. (B) Heatmap of DUSP genes in Jurkat cells. 
(C&D) Levels of Dusp2 mRNA in RAW264.7 cells at 6 h and 24 h, respectively. (E) Dusp2 
mRNA level in primary macrophages at 6 h. (F) Dusp2 mRNA level in Jurkat cells at 6 h. 
(G) Dusp2 mRNA level in HMC-1.1 cells at 4 h. (H) Dusp2 mRNA level in RAW264.7 
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cells treated with Dusp2 siRNA. (I) Levels of Dusp2, IL1β, and Cox2 mRNAs in 
RAW264.7 cells treated with Dusp2 siRNA in the presence and absence of LPS at 6 h.
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Figure 5. 
Suppression of the progression of CAIA by salubrinal. Note that CN=placebo, and 
Sal=salubrinal. (A) CAIA induction and salubrinal administration. (B) Hind paws 12 days 
after induction of CAIA. (C) Clinical scores. (D) Temporal changes in the thickness of fore 
and hind paws. (E) H&E staining of the hind paws. The scale bars are 200 µm (upper) and 
50 µm (lower). (F) Histological scores. The single and double asterisks indicate p<0.05 and 
p<0.01, respectively.
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Table 1
Real-time PCR primers and siRNA used in this study.
mouse
target forward primer backward primer
Cox2 5’-CCCCCACAGTCAAAGACACT-3’ 5’-CTCATCACCCCACTCAGGAT-3’
Dusp2 5’-TGGAAATCTTGCCCTACCTG-3 5’-CTCCTGGAACCAGGCACTTA-3’
IL1β 5’-GCCCATCCTCTGTGACTCAT-3’ 5’-AGGCCACAGGTATTTTGTCG-3’
GAPDH 5’-TGCACCACCAACTGCTTAG-3’ 5’-GGATGCAGGGATGATGTTC-3’
human
target forward primer backward primer
Dusp2 5’-TCTTGCCCTACCTGTTCCTG-3’ 5’-GGCACTGATCTCCACCATCT-3’
IL2 5’-GCAACTCCTGTCTTGCATTG-3’ 5’-GCCTTCTTGGGCATGTAAAA-3’
IL13 5’-GTACTGTGCAGCCCTGGAAT-3’ 5’-TTTACAAACTGGGCCACCTC-3’
TNF 5’-CAGAGGGCCTGTACCTCATC-3’ 5’-GGAAGACCCCTCCCAGATAG-3’
GAPDH 5’-GCACCGTCAAGGCTGAGAAC-3’ 5’-ATGGTGGTGAAGACGCCAGT-3’
siRNA
Dusp2 5’-GCAUCACAGCAGUUCUCAA-3’
non-specific control 5’-UGUACUGCUUACGAUUCGG-3’
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